2009-23: Long-term experience with adalimumab for refractory uveitis - a patient registry
Corticosteroids (CS) are the mainstay treatment of non-infectious uveitis, but long-term systemic administration shows multiple side effects. Reports of case series of patients treated with adalimumab (Humira®) for uveitis suggest that adalimumab is an effective and safe therapy for the management of refractory non-infectious uveitis. All patients treated for refractory uveitis of non-infectious cause in the Rotterdam Eye Hospital and the Department of Ophthalmology of the Erasmus Medical Center (EMC) in Rotterdam are included in the “Disease and Activity Tracking Tool” (DATT) database www.visiononline.nl to evaluate the efficacy and safety of adalimumab. The objective of this registry is to evaluate the efficacy and safety in clinical patients treated with adalimumab for refractory uveitis of non-infectious cause. Study endpoints are visual acuity, ocular inflammatory activity, cystoid macula edema and immunosuppressive therapies.